9000 Rockville Pike

Bethesda, MD, United States

9000 Rockville Pike

Bethesda, MD, United States
SEARCH FILTERS
Time filter
Source Type

Fitzhugh C.D.,9000 Rockville Pike | Abraham A.A.,George Washington University | Tisdale J.F.,9000 Rockville Pike | Hsieh M.M.,9000 Rockville Pike
Hematology/Oncology Clinics of North America | Year: 2014

Research has solidified matched sibling marrow, cord blood, or mobilized peripheral blood as the best source for allogeneic hematopoietic stem cell transplantation for patients with sickle cell disease, with low graft rejection and graft-versus-host disease (GVHD) and high disease-free survival rates. Fully allelic matched unrelated donor is an option for transplant-eligible patients without HLA-matched sibling donors. Unrelated cord transplant studies reported high GVHD and low engraftment rates. Haploidentical transplants have less GVHD, but improvements are needed to increase the low engraftment rate. The decision to use unrelated cord blood units or haploidentical donors depends on institutional expertise. © 2014.


PubMed | George Washington University and 9000 Rockville Pike
Type: Journal Article | Journal: Hematology/oncology clinics of North America | Year: 2014

Research has solidified matched sibling marrow, cord blood, or mobilized peripheral blood as the best source for allogeneic hematopoietic stem cell transplantation for patients with sickle cell disease, with low graft rejection and graft-versus-host disease (GVHD) and high disease-free survival rates. Fully allelic matched unrelated donor is an option for transplant-eligible patients without HLA-matched sibling donors. Unrelated cord transplant studies reported high GVHD and low engraftment rates. Haploidentical transplants have less GVHD, but improvements are needed to increase the low engraftment rate. The decision to use unrelated cord blood units or haploidentical donors depends on institutional expertise.


Strauss J.,9000 Rockville Pike | Alewine C.,9000 Rockville Pike | Figg W.D.,9000 Rockville Pike | Duffy A.,9000 Rockville Pike
Clinical and Translational Oncology | Year: 2015

Historically, patientsdiagnosed with metastatic pancreatic cancer have faced a grim prognosis. The survival benefit seen with systemic chemotherapies and even combinations thereof have been disappointing. However, growing data suggest that the microenvironment of pancreatic cancer may be contributing to this poor prognosis. This microenvironment has a dense fibrotic stroma, and is hypoxic and highly immunosuppressive, all of which pose barriers to treatment. Newer strategies looking to disrupt the fibrotic stroma, target hypoxic areas, and improve local immune responses in the tumor microenvironment are currently undergoing clinical evaluation and seem to offer great promise. In addition to these therapies, preclinical work evaluating novel cytotoxic agents including nanoparticles has also been encouraging. While much research still needs to be done, these strategies offer new hope for patients with pancreatic cancer. © 2015 The author(s)

Loading 9000 Rockville Pike collaborators
Loading 9000 Rockville Pike collaborators